Mitochon Pharmaceuticals

Mitochon Pharmaceuticals is a clinical-stage biotech company focused on developing drugs that target mitochondrial dysfunction to treat serious neurodegenerative and neuromuscular diseases. Their mission is to create meaningful therapies that modulate mitochondrial physiology to slow disease progression and improve patient outcomes. Mitochon aims to open the door for a broad range of disease-modifying therapies by correcting mitochondrial dysfunctions linked to various diseases.

Mitochon Pharmaceuticals

970 Cross Lane, Blue Bell, PA 19422

https://www.mitochonpharma.com/

Patents

Induced expression of brain derived neurotrophic factor (BDNF) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases

2023-08-08 • US-11717497-B2

View Details

DNP and DNP prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, traumatic brain injury, concussion, dry eye disease, hearing loss and/or metabolic diseases

2022-08-09 • US-11406642-B2

View Details

Induced expression of brain derived neurotrophic factor (BDNF) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases

2020-12-15 • US-10864173-B2

View Details

DNP and DNP prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, traumatic brain injury, concussion, dry eye disease, hearing loss and/or metabolic diseases

2020-02-04 • US-10548900-B2

View Details

Induced expression of brain derived neurotrophic factor (BDNF) for treatment of Neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases

2019-03-05 • US-10220006-B2

View Details

Induced expression of brain derived neurotrophic factor (BDNF) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases

2018-05-22 • US-9974755-B2

View Details

Show More (1)

What We Do

MP-101

A mitochondrial uncoupling prodrug aimed at treating neurodegenerative diseases such as ALS, Huntington's Disease, and Parkinson's Disease.

MP-201

A slow-release mitochondrial uncoupling prodrug designed for conditions like Traumatic Brain Injury and Multiple Sclerosis.

Digital Health Technologies

Personalized Medicine

Application Area

Neurotrauma/ Traumatic Brain Injury

Transplantation

Services

Preclinical Development

Diagnostics

Proteomics

Biologics

Cellular Therapy

Key People

Robert Alonso

Founder & CEO

John G. Geisler, PhD

Founder & Chief Scientific Officer

Marcus Keep MD

Acting Chief Medical Officer

News & Updates

Micro-Doses of DNP Preserve Motor and Muscle Function with a Period of Functional Recovery in Amyotrophic Lateral Sclerosis Mice

Research published on November 18, 2024, demonstrating the efficacy of micro-doses of DNP in ALS models.

European Medicines Agency (EMA) Greenlights Mitochon Pharmaceuticals to Initiate Phase I/IIa Biomarker Study in Neurodegenerative Diseases

Announcement on January 9, 2024, regarding the initiation of a biomarker study for neurodegenerative diseases.

Blast Wave Vision Loss Protection With MP-201 Exploratory Research Awarded to Walter Reed Army Institute of Research in Collaboration with Mitochon Pharmaceuticals

Announcement on August 21, 2023, about a research award for MP-201.

MP-101 and MP-201 Glaucoma Exploratory Research Grant Awarded to University of Montreal by BrightFocus Foundation in Collaboration with Mitochon Pharmaceuticals

Announcement on May 8, 2023, regarding a research grant for glaucoma.

Updated Drug Could Treat Traumatic Brain Injuries Linked to Increased Risk for Neurodegenerative Disease

An article discussing the potential of Mitochon’s drugs in treating traumatic brain injuries, published on May 6, 2024.